Form 4: Arcus Biosciences COO Jennifer Jarrett Reports Stock Transaction

Jennifer Jarrett, Chief Operating Officer of Arcus Biosciences, reports a transaction involving common stock due to tax withholding obligations and employee stock purchase plan.

Summary

• On June 15, 2024, Jennifer Jarrett, the Chief Operating Officer of Arcus Biosciences, engaged in a transaction involving the company's common stock.
• The transaction involved the net settlement of 12,670 shares to cover tax withholding obligations related to the vesting and settlement of previously granted Restricted Stock Units (RSUs).
• The price per share for this transaction was $16.97.
• Following the reported transaction, Jarrett beneficially owns 203,064 shares of Arcus Biosciences common stock, which includes 481 shares purchased on May 31, 2024, through the company's Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing reflects routine transactions related to executive compensation and employee stock purchase plan participation. There is no indication of unusual or concerning activity.

Positives

• The reporting person participates in the company's Employee Stock Purchase Plan, indicating confidence in the company's future.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates activity related to compensation and personal investment decisions.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders as it is related to tax obligations and employee benefits.

Key Dates